Literature DB >> 21351206

Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions.

Dan Turner1, Anne M Griffiths, Thomas D Walters, Tong Seah, James Markowitz, Marian Pfefferkorn, David Keljo, Jacob Waxman, Anthony Otley, Neal S LeLeiko, David Mack, Jeffrey Hyams, Arie Levine.   

Abstract

BACKGROUND: The Pediatric Crohn's Disease Activity Index (PCDAI) has become the standard outcome measure in pediatric Crohn's disease (CD) clinical research. Other versions have been proposed but without systematic evaluation. The aim was to assess validity and responsiveness of the abbreviated PCDAI (abbrPCDAI), short PCDAI (shPCDAI), and modified PCDAI (modPCDAI) as measures of disease activity and to compare these with a mathematically weighted version developed here (wPCDAI).
METHODS: The raw data from four prospectively collected datasets were used, totaling 437 children with CD (including two clinical trials). Discriminant validity utilized physician global assessment of disease activity (PGA), and construct validity the correlation with PGA and laboratory results. Feasibility and face validity were ascertained by a survey of 33 experts in pediatric CD.
RESULTS: The wPCDAI had better performance than the PCDAI in construct validity and responsiveness and it discriminated better between the disease activity categories (area under the receiver operator characteristic [ROC] 0.97; 95% confidence interval [CI]: 0.95-0.99). In comparison to the original PCDAI, the noninvasive versions (abbrPCDAI and shPCDAI) had lower face, construct, and discriminant validity but were judged to be significantly more feasible. The modPCDAI performed well in the construct validation but was consistently inferior in all other parameters. Cutoffs that correspond to remission, response, and gradations of disease activity were determined for each index.
CONCLUSIONS: The newly weighted wPCDAI performed better than the original PCDAI and is more feasible. The noninvasive versions (shPCDAI and abbrPCDAI) are inferior to the full PCDAI, but when needed in retrospective studies either may be equally used.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21351206     DOI: 10.1002/ibd.21649

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  50 in total

1.  Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network.

Authors:  J Dhaliwal; T D Walters; D R Mack; H Q Huynh; K Jacobson; A R Otley; J Debruyn; W El-Matary; C Deslandres; M E Sherlock; J N Critch; K Bax; E Seidman; P Jantchou; A Ricciuto; M Rashid; A M Muise; E Wine; M Carroll; S Lawrence; J Van Limbergen; E I Benchimol; P Church; A M Griffiths
Journal:  J Crohns Colitis       Date:  2020-05-21       Impact factor: 9.071

2.  Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.

Authors:  Kristyna Pospisilova; Jitka Siroka; Eva Karaskova; Ondrej Hradsky; Tereza Lerchova; Kristyna Zarubova; Ivana Copova; Lucie Gonsorcikova; Maria Velganova-Veghova; Irena Francova; Lubor Urbanek; Milos Geryk; Vladimir Mihal; Jiri Bronsky
Journal:  Paediatr Drugs       Date:  2021-03-11       Impact factor: 3.022

3.  Stability of Emotional and Behavioral Functioning in Youth with Inflammatory Bowel Disease.

Authors:  Bonney Reed-Knight; Debra Lobato; Sarah Hagin; Elizabeth L McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack H Nassau; Kristina Suorsa; Barbara Bancroft; Neal S LeLeiko
Journal:  Child Health Care       Date:  2013-10-22

4.  Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease.

Authors:  Peter C Church; Mary-Louise C Greer; Ruth Cytter-Kuint; Andrea S Doria; Anne M Griffiths; Dan Turner; Thomas D Walters; Brian M Feldman
Journal:  Pediatr Radiol       Date:  2017-03-10

5.  An exploration of family problem-solving and affective involvement as moderators between disease severity and depressive symptoms in adolescents with inflammatory bowel disease.

Authors:  Shana L Schuman; Danielle M Graef; David M Janicke; Wendy N Gray; Kevin A Hommel
Journal:  J Clin Psychol Med Settings       Date:  2013-12

6.  Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease.

Authors:  Ivana Copova; Ondrej Hradsky; Kristyna Zarubova; Lucie Gonsorcikova; Kristyna Potuznikova; Tereza Lerchova; Jiri Nevoral; Jiri Bronsky
Journal:  Eur J Pediatr       Date:  2018-08-20       Impact factor: 3.183

7.  Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease.

Authors:  Kriszta Molnár; Adám Vannay; Beáta Szebeni; Nóra Fanni Bánki; Erna Sziksz; Aron Cseh; Hajnalka Győrffy; Péter László Lakatos; Mária Papp; András Arató; Gábor Veres
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

8.  Rates and predictors of oral medication adherence in pediatric patients with IBD.

Authors:  Neal S LeLeiko; Debra Lobato; Sarah Hagin; Elizabeth McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack Nassau; Kristina Suorsa; Jason Shapiro; Barbara Bancroft
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

9.  Depressive symptoms in youth with inflammatory bowel disease compared with a community sample.

Authors:  Bonney Reed-Knight; Debra Lobato; Sarah Hagin; Elizabeth L McQuaid; Ronald Seifer; Sheryl J Kopel; Julie Boergers; Jack H Nassau; Kristina Suorsa; Barbara Bancroft; Jason Shapiro; Neal S Leleiko
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

10.  Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice.

Authors:  Jennifer L Dotson; Wallace V Crandall; Peixin Zhang; Christopher B Forrest; L Charles Bailey; Richard B Colletti; Michael D Kappelman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-02       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.